REVIEWS

We had recommended Jayant Agro Organics in Volume No. 33 Issue No. 40 (dated July 24, 2017) when the scrip was trading at Rs 996. Our recommendation was backed by factors like robust financial performance in FY17 and growing demand for castor oil. The compa­ny had issued 1:1 bonus shares to the shareholders in August 2017, which led to our recommendation price at Rs 498. We had recommended to hold the stock in Issue No. 51 (dated Oct. 9, 2017) when it was trading at Rs 458 as it had introduced new product line. The manage­ment expects improvement in margins in Q3FY18 and revenue to be around Rs 2200-2400 crore in FY18. The gradual uptick in the stock price is expected post FY18 performance. As our target date has been reached, we rec­ommended EXIT from the scrip.

We had recommended Jubilant Life Sciences in Volume No. 34 Issue No. 8 (dated Dec. 11, 2017) when the scrip was trading at Rs 690. Our recommendation was backed by factors such as good margins and launching of new product line. The Life Science Ingredient (LSI) segment has strong demand and strong performance is expected from the segment going forward. The company’s allergy business has grown consistently and has enabled it to gain further market share. It has strong order book in CMO business segment, which will boost its growth in the long run. The overall outlook of pharmaceuticals is positive going forward. As our target price has been achieved, we have recommended investors to BOOK PROFIT in the scrip.